AWA
REGN icon

Arkadios Wealth Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Arkadios Wealth Advisors’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$77.2K – 1773
2025
Q4 		$77.2K Buy
+100
New +$67.9K ﹤0.01% 1505

Other funds holding REGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
N
Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Arkadios Wealth Advisors's REGN Position: Q1 2026 in Review

Arkadios Wealth Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 36% in Q1 2026, buying an estimated $906K and bringing the position to 4,435 shares worth $3.43M. The position accounts for 0.06% of the portfolio, ranked #345.

Arkadios Wealth Advisors first reported a position in REGN in Q1 2020 and has held it in 13 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

  • Arkadios Wealth Advisors held 4,435 shares of Regeneron Pharmaceuticals worth $3.43M as of Q1 2026.
  • Arkadios Wealth Advisors bought 1,184 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $906K.
  • Regeneron Pharmaceuticals made up 0.06% of Arkadios Wealth Advisors's portfolio in Q1 2026, its #345 holding.
  • Arkadios Wealth Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 13 quarters since.
  • 1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Arkadios Wealth Advisors's 13F filing for Q1 2026, filed 18 May 2026.